BioNTech SE (BNTX) Reports Q4 EPS of EUR12.18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioNTech Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
March 30, 2022 6:00 AM EDTFourth quarter and full year revenues of 5.5 billion1 and 19.0 billion1, respectivelyFull year net income of 10.3 billion and fully diluted earnings per share of 39.63 ($46.872)Expect to authorize a share repurchase program of up to $1.5 billion over the next two years and will propose a special cash dividend of 2.00 per share, pending approval at the Annual General MeetingApproximately 2.6 billion doses of COMIRNATY®/BNT162b2 delivered to more than 165 countries and regions worldwide in 2021, including more than 1 billion doses to low- and middle-income... More
